Evidence map›Paper›PMID 38403442›Full record

ArticleBiotechnology journal2024

Engineering CREB-activated promoters for adenosine-induced gene expression.

John Robert Cox, Andrea Fox, Conor Lenahan, Liza Pivnik, Matthew Manion, John Blazeck

Open access · hybridAbstract read
In one paragraph

Article in Biotechnology journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

John Robert CoxSchool of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, Georgia, USA.
Andrea FoxSchool of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, Georgia, USA.
Conor LenahanSchool of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, Georgia, USA.
Liza PivnikSchool of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, Georgia, USA.
Matthew ManionSchool of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, Georgia, USA.
John BlazeckSchool of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0002-6110-2938
Georgia Institute of Technology · US

Funding

Synthetic metabolism to armor and enhance a new class of cell therapiesDP2CA280622 · NCI · GEORGIA INSTITUTE OF TECHNOLOGY · PI BLAZECK, JOHN JAMES · 2022 to 2025
$2.3M
NCI NIH HHS DP2 CA280622
6 · The paper itself

Abstract

Accumulation of the ribonucleoside, adenosine (ADO), triggers a cAMP response element binding protein (CREB)-mediated signaling pathway to suppress the function of immune cells in tumors. Here, we describe a collection of CREB-activated promoters that allow for strong and tunable ADO-induced gene expression in human cells. By optimizing number of CREB transcription factor binding sites and altering the core promoter region of CREB-based hybrid promoters, we created synthetic constructs that drive gene expression to higher levels than strong, endogenous mammalian promoters in the presence of ADO. These synthetic promoters are induced up to 47-fold by ADO, with minimal expression in their "off" state. We further determine that our CREB-based promoters are activated by other compounds that act as signaling analogs, and that combinatorial addition of ADO and these compounds has a synergistic impact on gene expression. Surprisingly, we also detail how background ADO degradation caused by the common cell culture media additive, fetal bovine serum (FBS), confounds experiments designed to determine ADO dose-responsiveness. We show that only after long-term heat deactivation of FBS can our synthetic promoters enable gene expression induction at physiologically relevant levels of ADO. Finally, we demonstrate that the strength of a CREB-based promoter is enhanced by incorporating other transcription factor binding sites.

Indexed as

AdenosineCyclic AMP Response Element-Binding ProteinAnimalsCyclic AMPGene ExpressionHumansMammalsPromoter Regions, GeneticTranscription, GeneticAdenosineCyclic AMPCyclic AMP Response Element-Binding Proteinadenosineimmunosuppressivepromoter engineeringsynthetic promoter

Identifiers

PMID38403442
PMCPMC10901447
OpenAlexW4392256380

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.